84475-07-0|Fce 22250|Fce 22250|-范德生物科技公司

Fce 22250

NMR下载 COA and HPLC MSDS下载
names：
Fce 22250
CAS号：
84475-07-0
MDL Number：
MF(分子式)： C44H58N4O12 MW(分子量)： 834.964
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,26E)-2,15,17,29-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-{[(2E)-2-(1-piperidinylmethylene)hydrazino]methylene}-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate
英文别名	Fce 22250; Fce-22250; Fce22250
CAS号	84475-07-0
Inchi	InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,45,50-52,54H,10-12,17-18H2,1-9H3,(H,47,56)/b14-13+,19-16+,23-15+,29-20+,46-21+/t22-,24+,25+,26+,30-,35-,36+,40+,44-/m0/s1
InchiKey	SRGITGUCGGVOQM-YNQXYWRISA-N
分子式 Formula	C44H58N4O12
分子量 Molecular Weight	834.964
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Fce 22250(CAS:84475-07-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Fce 22250 is a broad spectrum antibiotic active against Mycobacterium.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250. J Antibiot (Tokyo). 1985 Jun;38(6):779-86. PubMed PMID: 3839503.

[2]Ungheri D, Morvillo E, Sanfilippo A. [Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro]. G Ital Chemioter. 1983 May-Dec;30(2-3):97-100. Italian. PubMed PMID: 6329872.

[3] Zanetti S, Ungheri D, Castellani Pastoris M, Fadda G. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains. Drugs Exp Clin Res. 1987;13(10):631-4. PubMed PMID: 3428127.

[4] Amitani R, Kuze F. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Kekkaku. 1994 Nov;69(11):711-7. Review. Japanese. PubMed PMID: 7837725.

[5] Abeck D, Johnson AP, Alexander F, Korting HC, Ballard RC. In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med. 1988 Aug;64(4):233-4. PubMed PMID: 3139546; PubMed Central PMCID: PMC1194222.

6: Dickinson JM, Mitchison DA. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183-93. PubMed PMID: 2834843.7: Abeck D, Johnson AP, Dangor Y, Ballard RC. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. J Antimicrob Chemother. 1988 Oct;22(4):437-44. PubMed PMID: 3264554.8: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617.9: Vigevani A, Arlandini E, Ballabio M, Franceschi G, Gioia B, Vioglio S. Physico-chemical properties of FCE 22250, 3-(piperidinomethylazinomethyl)rifamycin SV, a new long-acting rifamycin. Farmaco Prat. 1985 May;40(5):131-40. PubMed PMID: 3839192.10: Liu L, Wang ZY, Li D, Sun SL. [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):58-62. Chinese. PubMed PMID: 1950587.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开